Newsbenzinga
Leerink Partners Maintains Outperform on Eli Lilly, Raises Price Target to $1316
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…